Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma
NCT04224337Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2020
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in pulmonary sarcomatoid carcinoma (PSC), sponsored by Seoul National University Hospital. Started Jun 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
pulmonary sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on NCT04224337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04224337.